Human HGFR/c-MET Antibody
Human HGFR/c-MET Antibody Summary
Glu25-Thr932
Accession # P08581
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of HGF R/c‑MET in MDA‑MB‑231 Human Cell Line by Flow Cytometry. MDA-MB-231 human breast cancer cell line was stained with Human HGF R/c-MET Monoclonal Antibody (Catalog # MAB3582, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0101B).
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: HGFR/c-MET
HGF R, also known as Met (from N-methyl-N’-nitro-N-nitrosoguanidine induced), is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. This generates a mature HGF R that is a disulfide-linked dimer composed of a 50 kDa extracellular alpha chain and a 145 kDa transmembrane beta chain (1, 2). The extracellular domain (ECD) contains a seven bladed beta -propeller sema domain, a cysteine-rich PSI/MRS, and four Ig-like E-set domains, while the cytoplasmic region includes the tyrosine kinase domain (3, 4). Proteolysis and alternate splicing generate additional forms of human HGF R which either lack of the kinase domain, consist of secreted extracellular domains, or are deficient in proteolytic separation of the alpha and beta chains (5-7). The sema domain, which is formed by both the alpha and beta chains of HGF R, mediates both ligand binding and receptor dimerization (3, 8). Ligand-induced tyrosine phosphorylation in the cytoplasmic region activates the kinase domain and provides docking sites for multiple SH2-containing molecules (9, 10). HGF stimulation induces HGF R downregulation via internalization and proteasome-dependent degradation (11). In the absence of ligand, HGF R forms non-covalent complexes with a variety of membrane proteins including CD44v6, CD151, EGF R, Fas, Integrin alpha 6/ beta 4, Plexins B1, 2, 3, and MSP R/Ron (12-19). Ligation of one complex component triggers activation of the other, followed by cooperative signaling effects (12-19). Formation of some of these heteromeric complexes is a requirement for epithelial cell morphogenesis and tumor cell invasion (12, 16, 17). Paracrine induction of epithelial cell scattering and branching tubulogenesis results from the stimulation of HGF R on undifferentiated epithelium by HGF released from neighboring mesenchymal cells (20). Genetic polymorphisms, chromosomal translocation, over-expression, and additional splicing and proteolytic cleavage of HGF R have been described in a wide range of cancers (1). Within the ECD, human HGF R shares 86-88% amino acid sequence identity with canine, mouse, and rat HGF R.
- Birchmeier, C. et al. (2003) Nat. Rev. Mol. Cell Biol. 4:915.
- Corso, S. et al. (2005) Trends Mol. Med. 11:284.
- Gherardi, E. et al. (2003) Proc. Natl. Acad. Sci. USA 100:12039.
- Park, M. et al. (1987) Proc. Natl. Acad. Sci. USA 84:6379.
- Crepaldi, T. et al. (1994) J. Biol. Chem. 269:1750.
- Prat, M. et al. (1991) Mol. Cell. Biol. 12:5954.
- Rodrigues, G.A. et al. (1991) Mol. Cell. Biol. 11:2962.
- Kong-Beltran, M. et al. (2004) Cancer Cell 6:75.
- Naldini, L. et al. (1991) Mol. Cell. Biol. 11:1793.
- Ponzetto, C. et al. (1994) Cell 77:261.
- Jeffers, M. et al. (1997) Mol. Cell. Biol. 17:799.
- Orian-Rousseau, V. et al. (2002) Genes Dev. 16:3074.
- Klosek, S.K. et al. (2005) Biochem. Biophys. Res. Commun. 336:408.
- Jo, M. et al. (2000) J. Biol. Chem. 275:8806.
- Wang, X. et al. (2002) Mol. Cell 9:411.
- Trusolino, L. et al. (2001) Cell 107:643.
- Giordano, S. et al. (2002) Nat. Cell Biol. 4:720.
- Conrotto, P. et al. (2004) Oncogene 23:5131.
- Follenzi, A. et al. (2000) Oncogene 19:3041.
- Sonnenberg, E. et al. (1993) J. Cell Biol. 123:223.
Product Datasheets
Citations for Human HGFR/c-MET Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
10
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
Authors: CH Kang, Y Kim, DY Lee, SU Choi, HK Lee, CH Park
Cancers, 2021-11-16;13(22):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL)
Authors: KD Wurster, M Costanza, S Kreher, S Glaser, B Lamprecht, N Schleussne, I Anagnostop, M Hummel, K Jöhrens, H Stein, A Molina, A Diepstra, B Gillissen, K Köchert, R Siebert, O Merkel, L Kenner, M Janz, S Mathas
Cancers, 2021-10-07;13(19):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery
Authors: S Di Franco, P Bianca, DS Sardina, A Turdo, M Gaggianesi, V Veschi, A Nicotra, LR Mangiapane, M Lo Iacono, I Pillitteri, S van Hooff, F Martorana, G Motta, E Gulotta, VL Lentini, E Martorana, ME Fiori, S Vieni, MR Bongiorno, G Giannone, D Giuffrida, L Memeo, L Colarossi, M Mare, P Vigneri, M Todaro, R De Maria, JP Medema, G Stassi
Nature Communications, 2021-08-18;12(1):5006.
Species: Human
Sample Types: Whole Tissue
Applications: ICC -
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma
Authors: F De Bacco, F Orzan, J Erriquez, E Casanova, L Barault, R Albano, A D'Ambrosio, V Bigatto, G Reato, M Patanè, B Pollo, G Kuesters, C Dell'Aglio, L Casorzo, S Pellegatta, G Finocchiar, PM Comoglio, C Boccaccio
Cell Reports, 2021-07-27;36(4):109455.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer
Authors: T Khan, AM Seddon, AG Dalgleish, S Khelwatty, N Ioannou, S Mudan, H Modjtahedi
Oncol Rep, 2020-10-22;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma
Authors: BW Stringer, BW Day, RCJ D'Souza, PR Jamieson, KS Ensbey, ZC Bruce, YC Lim, K Goasdoué, C Offenhäuse, S Akgül, S Allan, T Robertson, P Lucas, G Tollesson, S Campbell, C Winter, H Do, A Dobrovic, PL Inglis, RL Jeffree, TG Johns, AW Boyd
Sci Rep, 2019-03-20;9(1):4902.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell death.
Authors: Vogel S, Borger V, Peters C, Forster M, Liebfried P, Metzger K, Meisel R, Daubener W, Trapp T, Fischer J, Gawaz M, Sorg R
Cell Death Differ, 2015-01-09;22(7):1219-30.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
Authors: Carbonell W, DeLay M, Jahangiri A, Park C, Aghi M
Cancer Res, 2013-05-03;73(10):3145-54.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.
Authors: Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, Giordano S, Fafeur V, Tulasne D
Mol. Biol. Cell, 2009-03-18;20(9):2495-507.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels.
Authors: Riccioni R, Senese M, Diverio D, Riti V, Mariani G, Boe A, LoCoco F, Foa R, Peschle C, Sporn M, Testa U
Leuk. Res., 2008-03-04;32(8):1244-58.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
-
Does Human HGFR/c-MET Antibody, Catalog # MAB3582, bind to the alpha chain or beta chain of HGFR/c-MET?
The immunogen for MAB3582 (Recombinant human HGF R/cMET, aa Glu25-Thr932) spans both the alpha and beta chain regions of Human HGFR and we do not epitope map our antibodies. However, staining in flow cytometry detects a surface epitope. Since only the alpha chain is extracellular in location and the beta chain is transmembrane in location, the antibody likley binds the alpha chain of this protein.
Isotype Controls
Reconstitution Buffers
Secondary Antibodies
Reviews for Human HGFR/c-MET Antibody
Average Rating: 4 (Based on 4 Reviews)
Have you used Human HGFR/c-MET Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Detection of human HGFR/c-MET on epidermoid carcinoma cell line A-431. A-431 cells were treated with 100 nM of the human HGFR/c-MET antibody (catalog # MAB3582) or mouse IgG1 isotype control, followed by a secondary antibody goat a-mouse IgG Fc APC. Isotype control (RED), human HGFR/c-MET antibody (BLUE).
Antibody was printed on custom arrays and incubated with fluorescently labeled human EDTA plasma
